Gene · 6607
Papers3,510
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,081 to 1,100 of 3,510
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Gene Therapy Approach with an Emphasis on Growth Factors: Theoretical and Clinical Outcomes in Neurodegenerative Diseases. | Mol Neurobiol | 2022 | 34655056 | PubTator, text mining | PubMed |
| [Newborn screening program for spinal muscular atrophy]. | Nervenarzt | 2022 | 34652481 | PubTator, text mining | PubMed |
Addressing Today's Absorption, Distribution, Metabolism, and Excretion (ADME) Challenges in the Translation of In Vitro ADME Characteristics to Humans: A Case Study of the SMN2 mRNA Splicing Modifier Risdiplam. | Drug Metab Dispos | 2022 | 34620695 | PubTator, text mining | PubMed |
| Systematic review and meta-analysis determining the benefits of in vivo genetic therapy in spinal muscular atrophy rodent models. | Gene Ther | 2022 | 34611322 | PubTator, text mining | PubMed |
| Nusinersen by subcutaneous intrathecal catheter for symptomatic spinal muscular atrophy patients with complex spine anatomy. | Muscle Nerve | 2022 | 34606118 | PubTator, text mining | PubMed |
| A 20-year Clinical and Genetic Neuromuscular Cohort Analysis in Lebanon: An International Effort. | J Neuromuscul Dis | 2022 | 34602496 | PubTator, text mining | PubMed |
| Preparing n-of-1 Antisense Oligonucleotide Treatments for Rare Neurological Diseases in Europe: Genetic, Regulatory, and Ethical Perspectives. | Nucleic Acid Ther | 2022 | 34591693 | PubTator, text mining | PubMed |
| Cytochemical Characterization of Cerebrospinal Fluid Macrophage Inclusions in Pediatric Patients Receiving Intrathecal Nusinersen (SPINRAZA®) for Spinal Muscular Atrophy. | Acta Cytol | 2022 | 34515035 | PubTator, text mining | PubMed |
| Evaluation of Advanced Therapy Medicinal Products by the National Institute for Health and Care Excellence (NICE): An Updated Review. | Pharmacoecon Open | 2022 | 34415514 | PubTator, text mining | PubMed |
| Comparison of clinical pharmacogenetic recommendations across therapeutic areas. | Pharmacogenet Genomics | 2022 | 34412102 | PubTator, text mining | PubMed |
| Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination. | Pharmacol Ther | 2022 | 34403681 | PubTator, text mining | PubMed |
| [Thrombotic Microangiopathy (TMA) after Gene Replacemant Therapy (GRT) due to Spinal Muscular Atrophy: Case Summary and Recommendations for Treatment]. | Klin Padiatr | 2022 | 34388834 | PubTator, text mining | PubMed |
| Comprehensive transcriptome-wide analysis of spliceopathy correction of myotonic dystrophy using CRISPR-Cas9 in iPSCs-derived cardiomyocytes. | Mol Ther | 2022 | 34371182 | PubTator, text mining | PubMed |
| Regulation of Alternative Splicing during Epithelial-Mesenchymal Transition. | Cells Tissues Organs | 2022 | 34348273 | PubTator, text mining | PubMed |
| Understanding the Role of Histone Deacetylase and their Inhibitors in Neurodegenerative Disorders: Current Targets and Future Perspective. | Curr Neuropharmacol | 2022 | 34151764 | PubTator, text mining | PubMed |
| Novel genome-editing-based approaches to treat motor neuron diseases: Promises and challenges. | Mol Ther | 2022 | 33823304 | PubTator, text mining | PubMed |
| Alternative strategies in cardiac preclinical research and new clinical trial formats. | Cardiovasc Res | 2022 | 33693475 | PubTator, text mining | PubMed |
| Lessons Learned From Translational Research in Neuromuscular Diseases: Impact on Study Design, Outcome Measures and Managing Expectation. | Front Genet | 2021 | 36687260 | PubTator, text mining | PubMed |
| Changing the landscape of non-small cell lung cancer disparities. | J Cancer Biol | 2021 | 35929605 | PubTator, text mining | PubMed |
| Genome Editing in Medicine: Tools and Challenges. | Acta Med Litu | 2021 | 35637939 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6607/papers?page=55